These shares are still too expensive for new investors.
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The company has a potential life-saving catalyst in its portfolio, too.
Merck will sell the skin cancer drug under the brand name Keytruda.
With Ampion failure, Ampio's pipeline is worthless.
TheStreet's Jim Cramer says that a new treatment from Zoetis could help save pigs and drive down pork prices.
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
With the recent deal for DAVA, Endo is now one of the best health care stocks to own.
TheStreet's Jim Cramer continues to like Regeneron, but says it's too early for investors to jump into Conn's.
Results from Sunesis' phase III study in acute myeloid leukemia should be released this month or next.
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
A new study reports a huge potential advance against heart failure: a first-of-a-kind drug that lowered the chances of death or hospitalization by about 20%.
And the company has a new cancer drug on the market, plus a new insulin that should be approved in Europe.
Bank of Israel reduced its cash rate to a historic low of 0.25%. This decision could have an adverse impact on the dividend payment of Teva Pharmaceutical Industries.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV